Expanded PDMP access for all Schedule II–IV drugs Copied

The Prescription Drug Monitoring Program (PDMP) feature will be expanded to provide greater visibility into patients’ controlled substance histories.

What’s changing

Previously, PDMP reports were limited to Schedule II–IV opioids. With this update, the feature now encompasses all Schedule II–IV drugs, covering both opioid and non-opioid medications for initial prescriptions and renewals.

Practices with PDMP integration

When prescribing a Schedule II, III, or IV medication, a “View Report” button will appear within the PDMP section of the order details window (callout 1) and a “View PDMP Report” button will appear on the Medications page of the patient’s chart (callout 2). This functionality is available for practices integrated with their State PDMP through Bamboo Health or Logicoy.

By clicking this button, healthcare professionals can review the patient’s history with controlled substances and evaluate any potential risk of overdose prior to finalizing the prescription.

Practices not integrated with PDMP

For practices that are not integrated with Bamboo Health or Logicoy, the process remains straightforward while ensuring compliance. A “PDMP reviewed” checkbox will be clearly displayed, allowing users to manually select or deselect it (callout 3).

This action signifies that you reviewed the pertinent information regarding the patient’s history with controlled substances.

Why this matters

Improved Patient Safety: Your practice can now see a more complete picture of a patient’s medication history across all relevant controlled substances, helping to avoid duplicate therapies and identify potential misuse.

MIPS Compliance Support: This expansion helps practices participating in the Merit-based Incentive Payment System (MIPS) meet the requirements for the Query of PDMP measure, part of the Promoting Interoperability performance category.